Needham Thinks Esperion's Stock is Going to Recover
Markets Needham analyst Chad Messer maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $134.00. The company’s shares closed last Tuesday at $26.88, close to its 52-week low of $23.90. According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.1% and a 47.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics. The word on ...
Source: markets.co